quinazolines has been researched along with Cancer of Skin in 67 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (5.97) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (28.36) | 29.6817 |
| 2010's | 41 (61.19) | 24.3611 |
| 2020's | 3 (4.48) | 2.80 |
| Authors | Studies |
|---|---|
| Bobera, J; Dupuy, AJ; Feddersen, CR; Jennings, BM; Mullen, SA; Riordan, JD; Schillo, JL; Stipp, CS; Varzavand, A; Vaughn, HR; Voigt, AP; Wadsworth, LS; Zhu, EY | 1 |
| Alex, VV; Anto, RJ; Bava, SV; Chittalakkottu, S; Nisthul A, A; Retnakumari, AP; Shankar G, M; Sundaram, S | 1 |
| Chen, X; Guo, J; Liang, L; Liu, H; Liu, J; Liu, N; Peng, C; Qi, M; Su, J; Zhang, J; Zhao, S | 1 |
| Kitamura, S; Maeda, T; Yanagi, T | 1 |
| Cohen, PR; Udkoff, J | 1 |
| Chen, CM; Cheng, CY; Lin, KY; Lu, CY; Wu, YH | 1 |
| Lim, SY; Menzies, AM; Rizos, H | 1 |
| Feng, L; Ferrarotto, R; Ginsberg, L; Glisson, B; Kies, M; Kim, ES; Lippman, S; William, WN | 1 |
| Andersson, C; Blom, K; Edqvist, PH; Fryknäs, M; Gustafsson, MG; Jarvius, M; Larsson, R; Nazir, M; Nyberg, F; Nygren, P; Senkowski, W | 1 |
| Gaffney, DC; Simpson, F; Soyer, HP | 1 |
| Ali, FR; Lear, JT | 1 |
| Abel, EV; Amaravadi, RK; Aplin, AE; Basile, KJ; Ertel, A; Fortina, P; Karakousis, GC; Kugel, CH; Le, K; Lee, JB; Schuchter, LM; Witkiewicz, AK; Xu, W; Xu, X | 1 |
| Cai, P; Chen, W; Fang, X; Gao, Z; Gu, Y; Sun, Y; Xu, Q; Zhang, X | 1 |
| Emmert, S; Liu, N; Pletz, N; Schneider, P; Schön, M; Schön, MP; Seitz, CS; Zachmann, K; Ziegelbauer, K | 1 |
| Dranitsaris, G; Lacouture, ME | 1 |
| Chasapi, V; Soura, E; Stratigos, AJ | 1 |
| Adamus, G; Amundson, D; Boon, CJ; Haanen, JB; Jager, MJ; Kapiteijn, EH; Keunen, JE; Luyten, GP; Marinkovic, M; van Dijk, EH; van Herpen, CM | 1 |
| Uhara, H | 1 |
| Doddapaneni, R; Godugu, C; Mercer, R; Patel, AR; Singh, M; Singh, R | 1 |
| Cherpelis, B; Rudnick, EW; Thareja, S | 1 |
| Chen, Z; Wu, JH; Zhang, X; Zhao, J | 1 |
| Cataisson, C; Krymskaya, L; Mascia, F; McKinnon, KM; Schloemann, DT; Wolcott, KM; Yuspa, SH | 1 |
| Gilhar, A; Gorovitz, B; Hodak, E; Keren, A; Lubin, I; Moyal, L; Sherman, S; Yehezkel, S | 1 |
| Belli, C; Giovannini, M; Gregorc, V; Villa, E | 1 |
| Phillips, MA; Reznikova, TV; Rice, RH | 1 |
| Ashton, GH; Baldeschi, C; Brunton, VG; Canel, M; Doyle, B; Frame, MC; Green, TP; Mackintosh, LJ; Mason, SM; Sansom, OJ; Serrels, A; Serrels, B | 1 |
| Abdiu, A; Djerf, EA; Hallbeck, AL; Thunell, LK; Trinks, C; Walz, TM | 1 |
| Elenius, K; Grenman, R; Iivanainen, E; Kulmala, J; Lauttia, S; Salven, P; Tvorogov, D; Zhang, N | 1 |
| Agrawal, NS; Cronin, JC; Cruz, P; Lin, JC; Prickett, TD; Rosenberg, SA; Samuels, Y; Wei, X; Wunderlich, JR; Yates, KE | 1 |
| Ardinghi, C; Bani, MR; Bernasconi, S; Carraro, F; Ghilardi, C; Giavazzi, R; Naldini, A; Oliva, P; Silini, A | 1 |
| Agulnik, M; Guitart, J; Lacouture, ME; Reid, DC | 1 |
| Bulj, TK; Cetner, AS; Krunic, AL; Villano, JL | 1 |
| Dibirdik, I; Qazi, S; Uckun, FM | 1 |
| Chang, HC; Connolly, K; DiGiovanni, J; Kiguchi, K; Kitamura, T; Moore, T; Ruffino, L; Rumi, M; Treece, D | 1 |
| Katano, M; Morisaki, T; Nakafusa, Y; Nakashima, Y; Onishi, H; Yokohata, K | 1 |
| Hibino, M; Kudo, S; Minamiya, Y; Nakamura, M; Ogawa, J; Okuyama, M; Sasaki, Y; Tenma, K | 1 |
| Cranmer, L; Curiel-Lewandrowski, C; Engelhardt, C; Warneke, J | 1 |
| Botti, G; D'Antonio, A; De Luca, A; Hendrix, MJ; Hsu, MY; Lamura, L; Margaryan, N; Mari, E; Normanno, N; Pirozzi, G; Roma, C; Salomon, DS; Strizzi, L | 1 |
| Katsifis, A; Lin, HQ; Meriaty, H | 1 |
| Marghoob, AA; Tang, JY | 1 |
| Chambers, MS; El-Naggar, AK; Feng, L; Glisson, BS; Lewis, CM; Lustig, RA; Rosenthal, DI; Tang, X; Wan, F; Weber, RS; Wistuba, II | 1 |
| Aiba, S; Fujimura, T; Haga, T; Hashimoto, A; Hidaka, T; Mizuashi, M; Onami, K; Watabe, A | 1 |
| Buechner, SA; Erne, P; Joshi, MB; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ | 1 |
| Awada, A; Bastholt, L; Bonichon, F; de la Fouchardiere, C; Gómez, JM; Krause, T; Leboulleux, S; Leenhardt, L; Licour, M; Schlumberger, MJ; Soufflet, C; Tennvall, J | 1 |
| Commandeur, S; de Gruijl, FR; El Ghalbzouri, A; van Drongelen, V | 1 |
| Bossi, P; Cortelazzi, B; Licitra, L; Locati, LD; Maurichi, A; Perrone, F; Pilotti, S; Resteghini, C | 1 |
| Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A | 1 |
| Barrick, B; Fraga, G; Matthys, B | 1 |
| Carroll, WR; Clemons, L; Deep, NL; Desmond, R; Heath, CH; Magnuson, JS; Nabell, L; Rosenthal, EL; Spencer, S | 1 |
| Buechner, SA; Erne, P; Iezzi, G; Kyriakakis, E; Pfaff, D; Philippova, M; Resink, TJ; Schoenenberger, AW; Spagnoli, GC | 1 |
| Bagheri-Yarmand, R; Barnes, CJ; Clayman, GL; Hong, WK; Kumar, R; Mandal, M; Yang, Z | 1 |
| BALDWIN, RW; PALMER, HC; PARTRIDGE, MW | 1 |
| BALDWIN, RW; CUNNINGHAM, GJ; DEAN, HG; PARTRIDGE, MW; SURTEES, SJ; VIPOND, HJ | 1 |
| Ashida, M; Bito, T; Budiyanto, A; Ichihashi, M; Kunisada, M; Ueda, M | 1 |
| Aulmann, S; Bastert, G; Koehler, M; Kolay, S; Schneeweiss, A; Torode, J; Von Minckwitz, G | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| El-Abaseri, TB; Fuhrman, J; Hansen, LA; Shendrik, I; Tennant, RW; Trempus, C | 1 |
| Baltaci, M; Derler, AM; Fritsch, P; Höpfl, R; Sögner, P; Tzankov, A; Weber, F | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| de Waal, RM; Kats, G; Küsters, B; Leenders, WP; Roodink, I; Ruiter, DJ; Verrijp, K; Wesseling, P | 1 |
| Hermanns, JF; Piérard, GE; Quatresooz, P | 1 |
| Bélanger, K; Eisenhauer, EA; Lee, CW; Petrella, TM; Rao, SC; Savage, KJ; Seymour, L; Synold, TW; Tozer, RG; Wainman, N; Wood, L | 1 |
| Ben Ahmed, S; Blackwell, K; Boussen, H; Citrin, DL; DeSilvio, ML; Harris, J; Johnston, S; Kaufman, B; Lombardi, DP; LoRusso, P; Salazar, V; Spector, NL; Trudeau, M; Westlund, RE; Zaks, TZ | 1 |
| Billestrup, N; Brender, C; Kaltoft, K; Mikkelsen, G; Nielsen, M; Odum, N; Wasik, M; Zhang, Q | 1 |
| Cipák, L; Jantová, S; Kubíková, J; Maliar, T; Mikulásová, M; Rauko, P; Spirková, K; Stankovský, S; Urbancíková, M | 1 |
| Hecker, E; Pecar, S; Schara, M; Schmidt, R; Sorg, B | 1 |
| Baldwin, RW; Chayen, J; Diengdoh, JV | 1 |
9 review(s) available for quinazolines and Cancer of Skin
| Article | Year |
|---|---|
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.
Topics: Aged; Carcinoma; Carcinoma, Papillary; Humans; Immunohistochemistry; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Male; Neoplasms, Multiple Primary; Piperidines; Quinazolines; Skin Neoplasms; Thoracic Wall; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2017 |
The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Panitumumab; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin Neoplasms | 2014 |
Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
Topics: Anilides; Antineoplastic Agents; Benzamides; Biphenyl Compounds; Carcinoma, Basal Cell; Clinical Trials as Topic; Hedgehog Proteins; Humans; Pyridines; Quinazolines; Skin Neoplasms | 2013 |
Pharmacologic treatment options for advanced epithelial skin cancer.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Pyridines; Quality of Life; Quinazolines; Skin Neoplasms; Treatment Outcome | 2015 |
[Molecular target therapies for skin cancers].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; CTLA-4 Antigen; Enzyme Inhibitors; Gefitinib; Humans; MAP Kinase Kinase Kinases; Melanoma; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Quinazolines; Skin Neoplasms | 2015 |
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden | 2016 |
Emerging treatments and signaling pathway inhibitors.
Topics: Aminoquinolines; Anilides; Antineoplastic Agents; Basal Cell Nevus Syndrome; Benzamides; Carcinoma, Basal Cell; Deoxyribonuclease (Pyrimidine Dimer); Fluorouracil; Hedgehog Proteins; Humans; Imiquimod; Photochemotherapy; Pyridines; Quinazolines; Retinoids; Secondary Prevention; Signal Transduction; Skin Neoplasms; Viral Proteins | 2011 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
9 trial(s) available for quinazolines and Cancer of Skin
| Article | Year |
|---|---|
Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Skin Neoplasms | 2017 |
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Middle Aged; Models, Biological; Quinazolines; Risk Factors; ROC Curve; Skin Neoplasms | 2014 |
Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
Topics: Adult; Aged; Autoantibodies; Benzimidazoles; Central Serous Chorioretinopathy; Cross-Sectional Studies; Drug Combinations; Electrooculography; Electroretinography; Eye Proteins; Female; Fluorescein Angiography; Humans; Male; Melanoma; Melanoma, Cutaneous Malignant; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Prospective Studies; Protein Kinase C; Pyrroles; Quinazolines; Skin Neoplasms; Subretinal Fluid; Tomography, Optical Coherence; Uveal Neoplasms; Visual Acuity | 2015 |
A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2012 |
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Topics: Adenocarcinoma, Follicular; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Double-Blind Method; Electrocardiography; ErbB Receptors; Female; Heart Conduction System; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Survival Analysis; Thyroid Cancer, Papillary; Thyroid Neoplasms; Young Adult | 2012 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Melanoma; Middle Aged; Quinazolines; Receptor, IGF Type 1; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2013 |
Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Skin Neoplasms; Stomatitis | 2013 |
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Drug Delivery Systems; Eye Neoplasms; Female; Humans; Kinesins; Male; Melanoma; Middle Aged; Mucous Membrane; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin Neoplasms; Treatment Outcome | 2008 |
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cohort Studies; Female; Humans; Immunoenzyme Techniques; Inflammation; Lapatinib; Lymphatic Metastasis; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Sensitivity and Specificity; Skin Neoplasms | 2008 |
49 other study(ies) available for quinazolines and Cancer of Skin
| Article | Year |
|---|---|
Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma.
Topics: Antineoplastic Agents; Benzodioxoles; Drug Resistance, Neoplasm; Guanine Nucleotide Exchange Factors; Humans; Melanoma; Melanoma, Cutaneous Malignant; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-vav; Quinazolines; Signal Transduction; Skin Neoplasms; src-Family Kinases; Vemurafenib | 2019 |
Pre-clinical evidences for the efficacy of tryptanthrin as a potent suppressor of skin cancer.
Topics: Animals; Drug Screening Assays, Antitumor; gamma-Aminobutyric Acid; Ki-67 Antigen; Mice; Neoplasm Proteins; Proliferating Cell Nuclear Antigen; Quinazolines; Skin Neoplasms; Tetradecanoylphorbol Acetate | 2020 |
Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylamines; Cell Line, Tumor; Cisplatin; DNA Damage; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Melanoma, Cutaneous Malignant; Mice; Quinazolines; Reactive Oxygen Species; Skin Neoplasms; Ubiquitin Thiolesterase; Ubiquitin-Specific Proteases; Xenograft Model Antitumor Assays | 2020 |
Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma.
Topics: Aged; Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Piperidines; Proto-Oncogene Mas; Quinazolines; Skin Neoplasms | 2020 |
Regulation of miR-21 expression in human melanoma via UV-ray-induced melanin pigmentation.
Topics: alpha-MSH; Animals; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Gefitinib; Humans; Melanins; Melanoma; Melanoma, Experimental; Mice; MicroRNAs; Phosphorylation; Pigmentation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin Neoplasms; Ultraviolet Rays | 2017 |
Targeting tumor cells based on Phosphodiesterase 3A expression.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; Cyclic Nucleotide Phosphodiesterases, Type 3; Female; Gastrointestinal Stromal Tumors; Gene Expression; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Organ Specificity; Organoplatinum Compounds; Oxaliplatin; Phosphodiesterase Inhibitors; Pyridazines; Quinazolines; RNA, Messenger; Skin Neoplasms | 2017 |
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.
Topics: Cell Survival; Enzyme Inhibitors; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Lapatinib; MAP Kinase Kinase Kinases; Melanoma; Oligonucleotide Array Sequence Analysis; Phosphorylation; Quinazolines; raf Kinases; Receptor, ErbB-3; Signal Transduction; Skin Neoplasms; Sulfonamides; Transcription, Genetic | 2013 |
Icotinib, a potent and specific EGFR tyrosine kinase inhibitor, inhibits growth of squamous cell carcinoma cell line A431 through negatively regulating AKT signaling.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Crown Ethers; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Humans; Mice; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Quinazolines; Signal Transduction; Skin Neoplasms | 2013 |
The novel PI3 kinase inhibitor, BAY 80-6946, impairs melanoma growth in vivo and in vitro.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Enzyme Inhibitors; Humans; In Vitro Techniques; Melanoma; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Caco-2 Cells; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemistry, Pharmaceutical; Excipients; Gefitinib; Humans; Mice, Nude; Proteomics; Quinazolines; Rats; Rats, Sprague-Dawley; Skin Neoplasms; Solubility; Survival Analysis; Xenograft Model Antitumor Assays | 2016 |
Case Report: Bazex Syndrome Associated With Pulmonary Adenocarcinoma.
Topics: Acitretin; Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Biopsy, Needle; Bone Neoplasms; Carcinoma, Basal Cell; Dexamethasone; Drug Therapy, Combination; Follow-Up Studies; Gefitinib; Humans; Hypotrichosis; Immunohistochemistry; Lung Neoplasms; Lymph Nodes; Male; Paraneoplastic Syndromes; Quinazolines; Radiography; Rare Diseases; Risk Assessment; Skin Neoplasms; Treatment Outcome | 2016 |
Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas.
Topics: Animals; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Immunocompetence; Keratinocytes; Mice; Protein Kinase Inhibitors; Quinazolines; Skin Neoplasms | 2016 |
Oncogenic role of microRNA-155 in mycosis fungoides: an in vitro and xenograft mouse model study.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Female; Genes, cdc; HEK293 Cells; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Lentivirus; Mice, SCID; MicroRNAs; Mycosis Fungoides; Phenotype; Quinazolines; Sezary Syndrome; Skin Neoplasms; Transduction, Genetic; Transplantation, Heterologous; Vorinostat | 2017 |
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
Topics: Adenocarcinoma; Antineoplastic Agents; Diagnosis, Differential; Drug Therapy, Combination; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Letrozole; Lung Neoplasms; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Skin Neoplasms; Triazoles | 2008 |
Arsenite suppresses Notch1 signaling in human keratinocytes.
Topics: Amyloid Precursor Protein Secretases; Arsenites; Calcium-Binding Proteins; Cell Differentiation; Enzyme Inhibitors; Humans; Insulin-Like Growth Factor I; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Keratinocytes; Membrane Proteins; Models, Biological; Protein Binding; Quinazolines; Receptor, Notch1; Receptors, Notch; Serrate-Jagged Proteins; Signal Transduction; Skin Neoplasms; Tyrphostins | 2009 |
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
Topics: Adult; Aged; Animals; Anticarcinogenic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Female; Humans; Keratinocytes; Keratosis; Male; Mice; Middle Aged; Papilloma; Precancerous Conditions; Quinazolines; Skin Neoplasms; src-Family Kinases; Tetradecanoylphorbol Acetate | 2009 |
ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Melanoma; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin Neoplasms; STAT3 Transcription Factor | 2009 |
The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
Topics: Animals; Antigens; Antineoplastic Agents; Blood Vessels; Bone Marrow Cells; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; ErbB Receptors; Gefitinib; Humans; Image Processing, Computer-Assisted; Melanoma; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Pericytes; Protein Kinase Inhibitors; Proteoglycans; Quinazolines; Skin Neoplasms | 2009 |
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; ErbB Receptors; Humans; Lapatinib; Melanoma; Mice; Mutation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-4; RNA Interference; Skin Neoplasms | 2009 |
Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype.
Topics: Animals; Cell Line, Tumor; Cell Movement; Disease Progression; Humans; Melanoma; Mice; Mice, SCID; Neoplasm Metastasis; Pyrroles; Quinazolines; Receptor, PAR-1; Skin Neoplasms | 2010 |
Treatment of multiple keratoacanthomas with erlotinib.
Topics: Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Keratoacanthoma; Male; Neoplasms, Multiple Primary; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Skin Neoplasms; Treatment Outcome | 2010 |
Refractory aggressive keratoacanthoma centrifugum marginatum of the scalp controlled with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Keratoacanthoma; Protein Kinase Inhibitors; Quinazolines; Scalp; Skin Neoplasms; Treatment Outcome | 2010 |
Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase.
Topics: Administration, Topical; Animals; Antimutagenic Agents; Dermatitis; ErbB Receptors; Female; Janus Kinase 3; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mutagenicity Tests; Neoplasms, Radiation-Induced; Protein Kinase Inhibitors; Quinazolines; Radiation Injuries, Experimental; Skin Neoplasms; Ultraviolet Rays | 2010 |
Dual inhibition of both the epidermal growth factor receptor and erbB2 effectively inhibits the promotion of skin tumors during two-stage carcinogenesis.
Topics: Algorithms; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Progression; Drug Evaluation, Preclinical; ErbB Receptors; Gene Expression Regulation, Neoplastic; Mice; Mice, Transgenic; Neoplasms, Glandular and Epithelial; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Skin Neoplasms; Treatment Outcome | 2010 |
Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer.
Topics: Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Mastectomy; Meningeal Carcinomatosis; Middle Aged; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Skin Neoplasms | 2011 |
[A case of lung cancer with skin metastases responding to erlotinib].
Topics: Aged; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin Neoplasms | 2011 |
Metastatic cutaneous squamous cell carcinoma responding to erlotinib therapy.
Topics: Axilla; Biopsy, Needle; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Shoulder; Skin Neoplasms; Treatment Outcome | 2011 |
Expression and functional role of CRIPTO-1 in cutaneous melanoma.
Topics: Activin Receptors, Type I; Benzamides; Benzodioxoles; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dioxoles; Flow Cytometry; GPI-Linked Proteins; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Melanoma; Neoplasm Invasiveness; Neoplasm Proteins; Protein-Tyrosine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms; Smad Proteins; src-Family Kinases; Tumor Cells, Cultured | 2011 |
Prediction of synergistic antitumour effect of gefitinib and radiation in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Melanoma; Phosphorylation; Quinazolines; Radiation, Ionizing; Skin Neoplasms | 2011 |
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lapatinib; Liver Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Scalp; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
T-Cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: impact on cell motility.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lapatinib; Membrane Microdomains; Quinazolines; rho GTP-Binding Proteins; Signal Transduction; Skin Neoplasms | 2012 |
Epidermal growth factor receptor activation and inhibition in 3D in vitro models of normal skin and human cutaneous squamous cell carcinoma.
Topics: Adult; Carcinoma, Squamous Cell; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines; Skin; Skin Neoplasms | 2012 |
Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lymphatic Metastasis; Male; Quinazolines; Sirolimus; Skin Neoplasms; Skin Ulcer; TOR Serine-Threonine Kinases | 2012 |
Ulcerated plaques in the pelvic region of an adult female.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Genital Neoplasms, Female; Humans; Lapatinib; Middle Aged; Neoplasm Invasiveness; Quinazolines; Skin Neoplasms; Skin Ulcer | 2012 |
T-cadherin loss promotes experimental metastasis of squamous cell carcinoma.
Topics: Animals; Cadherins; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Endothelial Cells; ErbB Receptors; Gefitinib; Human Umbilical Vein Endothelial Cells; Humans; Immunoblotting; Keratinocytes; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Confocal; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Skin Neoplasms; Transendothelial and Transepithelial Migration; Transplantation, Heterologous | 2013 |
Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Movement; Cell Survival; Cells, Cultured; Cytoskeleton; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Keratinocytes; MAP Kinase Signaling System; Microscopy, Fluorescence; Neoplasm Invasiveness; p21-Activated Kinases; Phenotype; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin Neoplasms | 2003 |
Studies on tricycloquinazoline carcinogenesis: interaction of carcinogen with skin components.
Topics: Carcinogenesis; Carcinogens; Humans; Quinazolines; Skin; Skin Neoplasms | 1962 |
FURTHER STUDIES ON THE INFLUENCE OF PERIPHERAL RING SUBSTITUTION ON THE CARCINOGENICITY OF TRICYCLOQUINAZOLINE.
Topics: Carcinogens; Chemistry, Pharmaceutical; Heterocyclic Compounds; Mice; Neoplasms, Experimental; ortho-Aminobenzoates; Papilloma; Pharmacology; Quinazolines; Research; Skin Neoplasms; Toxicology | 1965 |
Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells.
Topics: Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA-Binding Proteins; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Mitogen-Activated Protein Kinases; Nuclear Proteins; Phosphoproteins; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quinazolines; Repressor Proteins; RNA, Messenger; Skin Neoplasms; Telomerase; Transforming Growth Factor alpha; Tyrphostins | 2003 |
Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gefitinib; Humans; Lymph Nodes; Middle Aged; Quinazolines; Receptors, Growth Factor; Remission Induction; Skin Neoplasms; Trastuzumab | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
Chemoprevention of UV light-induced skin tumorigenesis by inhibition of the epidermal growth factor receptor.
Topics: Animals; Anticarcinogenic Agents; Cell Proliferation; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Hyperplasia; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasms, Radiation-Induced; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Skin; Skin Neoplasms; Tyrphostins; Ultraviolet Rays | 2005 |
Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Facial Neoplasms; Gefitinib; Humans; Male; Quinazolines; Skin Neoplasms | 2005 |
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.
Topics: Angiogenesis Inhibitors; Animals; Brain Neoplasms; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Piperidines; Pulmonary Embolism; Quinazolines; Skin Neoplasms; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2007 |
Erlotinib-responsive actinic keratoses.
Topics: Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Humans; Inflammation; Keratosis; Male; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Skin Neoplasms; Sunlight | 2007 |
STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
Topics: Cell Transformation, Neoplastic; Dimethyl Sulfoxide; DNA-Binding Proteins; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Dominant; Humans; Interferon-alpha; Interferon-gamma; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Mutation; Mycosis Fungoides; Neoplasm Proteins; Protein Biosynthesis; Proteins; Quinazolines; Recombinant Fusion Proteins; Repressor Proteins; RNA, Messenger; RNA, Neoplasm; Sezary Syndrome; Skin Neoplasms; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Trans-Activators; Transcription Factors; Transcription, Genetic; Transfection; Tumor Cells, Cultured; Tyrphostins | 2001 |
Biological activity of some 4-anilinoquinazolines: cytotoxic, genotoxic and antiprotease effects, induction of necrosis and changes of actin cytoskeleton.
Topics: Animals; CHO Cells; Cricetinae; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Leukemia; Melanoma; Mice; Mutagenicity Tests; Necrosis; Protease Inhibitors; Quinazolines; Skin Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2001 |
Spin-labeled phorbol esters and their interactions with cellular membranes. III. Skin irritant and tumor-promoting activities of spin-labeled phorbol-12,13-diesters and relationships to their particular structures.
Topics: Animals; Female; Indicators and Reagents; Irritants; Mice; Mice, Inbred Strains; Molecular Structure; Quinazolines; Skin; Skin Neoplasms; Spin Labels; Structure-Activity Relationship | 1988 |
Histochemical comparison of the effects of a carcinogenic and a non-carcinogenic derivative of tricycloquinazoline.
Topics: Animals; Carcinogens; DNA; Electron Transport Complex IV; Glycerolphosphate Dehydrogenase; Histocytochemistry; Hyperplasia; L-Lactate Dehydrogenase; Mice; Neoplasms, Experimental; Phosphogluconate Dehydrogenase; Quinazolines; Skin; Skin Neoplasms; Succinate Dehydrogenase; Sulfhydryl Compounds | 1970 |